Elanco Animal Health Incorporated Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination
Elanco Animal Health Incorporated (ELAN) reported Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Notes
us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination · last filed 2022-02-28
- Elanco Animal Health Incorporated contract with customer, liability, increase (decrease) for contract acquired in business combination for the quarter ending 2021-12-31 was $0.00.
- Elanco Animal Health Incorporated contract with customer, liability, increase (decrease) for contract acquired in business combination for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Elanco Animal Health Incorporated contract with customer, liability, increase (decrease) for contract acquired in business combination for the quarter ending 2020-12-31 was -$4.00M.
- Elanco Animal Health Incorporated contract with customer, liability, increase (decrease) for contract acquired in business combination for the quarter ending 2020-09-30 was $78.00M.
- Elanco Animal Health Incorporated contract with customer, liability, increase (decrease) for contract acquired in business combination for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Elanco Animal Health Incorporated contract with customer, liability, increase (decrease) for contract acquired in business combination for fiscal 2020 was $74.00M.
- Elanco Animal Health Incorporated contract with customer, liability, increase (decrease) for contract acquired in business combination for fiscal 2019 was $0.00.
| Period end | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination 3 month | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination 3 month as first filed | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination 6 month | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination 9 month | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination 9 month as first filed | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination 12 month | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | |||||
| 2020-12-31 | -$4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $74.00M derived: sum of 2 quarters · filed 2022-02-28 | $74.00M 10-K · filed 2022-02-28 | $49.60M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $78.00M 10-Q · filed 2021-11-05 | $20.80M 10-Q · filed 2020-11-06 | $78.00M 10-Q · filed 2021-11-05 | $20.80M 10-Q · filed 2020-11-06 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |